

11 March 2010 EMA/HMPC/5513/2010 Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on *Potentilla erecta* (L.) Raeusch., rhizoma

Draft

Discussion in Working Party on Community monographs and Community	January 2010
list (MLWP)	March 2010
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	
for consultation	11 March 2010
End of consultation (deadline for comments). Comments should be	
provided using this template to hmpc.secretariat@ema.europa.eu	15 August 2010
Rediscussion in Working Party on Community monographs and	
Community list (MLWP)	
Adoption by Committee on Herbal Medicinal Products (HMPC)	

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional
	use; Potentilla erecta (L.) Raeusch., Tormentillae rhizoma; tormentil

BG (bălgarski):	LT (lietuvių kalba):
CS (čeština):	LV (latviešu valoda):
DA (dansk):	MT (malti):
DE (Deutsch): Tormentillwurzelstock, Blutwurz	NL (nederlands):
EL (elliniká):	PL (polski):
EN (English):	PT (português):
ES (espanol):	RO (română):
ET (eesti keel):	SK (slovenčina):
FI (suomi):	SL (slovenščina):
FR (français):	SV (svenska):
HU (magyar):	IS (íslenska):
IT (italiano):	NO (norsk):

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7051 **E-mail** info@ema.europa.eu **Website** www.ema.europa.eu



An agency of the European Union

 \odot European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged.

Community herbal monograph on Potentilla erecta (L.) Raeusch., rhizoma

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1,2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	<i>Potentilla erecta</i> (L.) Raeusch., rhizoma (tormentil)
	i) Herbal substance not applicable
	 ii) Herbal preparations a) Comminuted herbal substance b) Tincture (ratio drug : extraction solvent 1:5), extraction solvent ethanol 70% v/v³ c) Tincture (ratio drug : extraction solvent 1:5), extraction solvent ethanol 45% v/v d) Liquid extract (DER 1:1), extraction solvent ethanol 25% v/v
	e) Dry extract (DER 3.5-4.5:1), extraction solvent ethanol 60% v/v

1 The material complies with the Ph. Eur. monograph (ref.: 01/2008: 1478). *2* The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. ³ The tincture complies with the Eur. Ph. monograph (ref.: 01/2008: 1895).

3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as herbal tea for oral use.
	Comminuted herbal substance for infusion or decoction preparation for oromucosal use.
	Herbal preparations a), c), d) and e) in liquid dosage forms for oral use.
	Herbal preparation b) in liquid dosage forms for oromucosal use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product for symptomatic treatment of mild diarrhoea.
	Indication 2)
	Traditional herbal medicinal product for the symptomatic treatment of minor inflammations of the oral mucosa.
	The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use	Traditional use
	Posology
	Adults and elderly
	Indication 1 (oral use)
	a) Comminuted herbal substance:
	As <i>infusion</i> : single dose 1.4-4 g, several
	times daily up to a maximum daily dose of
	12 g comminuted herbal substance.

Well-established use	Traditional use
	As <i>decoction</i> : single dose 1.4-3 g, several times daily up to a maximum daily dose of 6 g comminuted herbal substance.
	b) Single dose: 1-2 ml in water; 3 times daily.
	c) Single dose 2-4 ml, 3 times daily.
	d) Single dose 2-4 ml, 3 times daily.
	e) Single dose 400 mg, 3 times daily.
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Adults and elderly
	Indication 2 (oromucosal use)
	a) Comminuted herbal substance: As infusion: 1.3 – 2 g per 100 ml of water. As decoction: 0.8 – 3 g per 100 ml of water.
	Rinse the mouth several times daily.
	b) Single dose: 1-5 ml per 150 ml of water.
	Rinse the mouth several times daily.
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	Indication 1:
	If the symptoms persist longer than 3 days during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Indication 2:
	If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Indication 1:
	Oral use.
	Indication 2:

Well-established use	Traditional use
	Oromucosal use.

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	Indication 1:
	If recurrent diarrhoea or bloody stools occur a doctor or a qualified health care practitioner should be consulted.
	Indications 1 and 2:
	The use in children and adolescents under 18 years of age has not been established due to lack of adequate data.
	If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	For tinctures containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	Indication 1:
	Internal absorption of concomitantly administered medicine may be delayed. For this reason the product should be taken 1 hour or more before or after intake of other medicinal products.
	Indication 2:
	None reported.

4.6. Pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established.
	In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	Indication 1:
	Mild stomach complains with the symptoms nausea and vomiting may occur in sensitive patients. The frequency is not known.
	If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.
	Indication 2:
	None known.
	If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c (1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c (1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation/last revision

11 March 2010